imported post
From Briefing.com: 4:23PM Weekly Wrap: The word of the week was "conundrum," and it went to the critical issue for the stock market.
On Wednesday, Federal Reserve Chairman Greenspan testified on monetary policy before the Senate Banking Committee. He said the economy is on a firm path, and that conclusion is widely accepted. He also suggested that inflation is "well anchored" but that the Fed needed to remain vigilant. Most of the headlines were about his statement that "the broadly unanticipated behavior of world bond markets remains a conundrum." By that he meant that long-term interest rates have remained surprisingly low even as the economy has strengthened, inflation has firmed, and short-term rates have gone up sharply.
The surprisingly low long-term interest rates have been of critical support to the stock market. If long rates start rising, that would affect valuation models and create a more attractive investment alternative to stocks. By the end of the week, the risk of higher rates started weighing on stocks.
The 10-year note yield reacted almost immediately. The yield ended last week at 4.09%. After Greenspan's comments, the yield rose to 4.15% and ended the week at 4.25%. There is reason to believe that the rate will keep rising.
First, Greenspan made it clear that the Fed will continue to raise short-term rates. Second, inflation may be picking up, or at least inflation concerns that could drive rates higher. On Friday, the January core PPI number came in at a surprisingly strong +0.8%. The gain reflected widespread price increases that suggest companies have greater pricing power than in the past. If so, overall inflation could inch higher in 2005. That would be a negative for financial markets.
Meanwhile, the fourth quarter earnings numbers continued to be very good. In fact, the aggregate increase for operating earnings for the S&P 500 now looks to come in near 20%. That is on top of a 28% gain in the fourth quarter last year. Applied Materials, Nordstrom, Coca-Cola, Hewlett-Packard, Target, and Wal-Mart were among the companies with good reports.
The market got no boost from the reports, however. Instead, this "old" news from the fourth quarter took a back seat to indications of an earnings slowdown in the first quarter. The number of companies guiding earnings estimates lower increased significantly from recent quarters. This has the market concerned that earnings growth will slow to 5% to 7% in the first quarter.
The economic reports this past week were mixed, but did not undermine expectations of 3% or greater real GDP growth in the first quarter. January retail sales were down 0.4% because of a 3.3% drop in auto sales. Excluding autos, sales were up a good 0.6%. January industrial production was unchanged, but that was due to a 3% drop in utility output, as manufacturing output was up 0.4%. New claims fell to the lowest level in four years. Housing starts reached record levels. None of the reports had much impact, however, as they did not alter economic expectations. The PPI report on Friday was far more important.
In terms of stock sectors, energy and materials companies continued to do well. Financial and healthcare stocks, the traditional leaders for the market, continued to struggle.
The market got a bounce in recent weeks after it became apparent that the fourth quarter earnings reports were excellent. That largely erased the early January weakness. Now the focus is shifting to interest rates and inflation. That creates some risk. There is little doubt about the economic and earnings outlook. It is the puzzle of interest rates and inflation that has to be solved. The market started to show concern about those issues this week, and a continued focus on those factors could hamper enthusiasm for stocks in the weeks ahead. --Dick Green, Briefing.com
Code:
Index Started Week Ended Week Change %Change YTD
DJIA 10796.01 10785.22 -10.79 -0.1 % 0 %
Nasdaq 2076.66 2058.62 -18.04 -0.9 % -5.4 %
S&P 500 1205.30 1201.59 -3.71 -0.3 % -0.9 %
Russell 2000 634.76 630.13 -4.63 -0.7 % -3.3 %
Close Dow +30.96 at 10785.22, S&P +0.84 at 1201.59, Nasdaq -2.72 at 2058.62: PPI and FDA were the acronyms of the day... The former contained bad news for the market while the latter contained good news... With a long weekend ahead of us, we'll start with the bad and end with the good... With respect to the January PPI report, the bad was its core component (excludes food and energy), which showed a surprising 0.8% increase versus the consensus estimate that called for a more modest 0.2% increase...
A big spike in tobacco prices (+3.4%) had something to do with the surprise, but nontheless, in light of Greenspan's recent testimony, the market wasn't inclined to dismiss the spike as an aberration... The concern about rising inflation, and the angst ahead of Wednesday's Consumer Price Index report, was palpable in the Treasury market where the yield on the benchmark 10-yr note jumped 8 basis points to 4.26% and the yield on the 30-yr bond rose 7 basis points to 4.65%... This jump in rates had the stock market on edge throughout the session, especially the financial sector (-0.98%), which held the broader market back all day...
To few people's surprise, rate-sensitive areas like homebuilding, utilities, brokerage, consumer finance, thrifts & mortgage, and diversified banks populated the list of worst-performing S&P industry groups... Per usual, the energy sector (+2.23%) bucked the broader trend and turned in a strong performance that was paced by the exploration and production group (+2.96%) and was highlighted by a gain in ExxonMobil (XOM 59.41, +1.28) that catapulted the oil company into the position of biggest company by market cap at approx. $384 bln...
Separately, the FDA's positive impact on the market stemmed from an advisory panel's recommendation that Merck's (MRK 32.61, +3.76) Vioxx drug should be reintroduced to the market and that Pfizer's (PFE 26.80, +1.74) Celebrex and Bextra drugs should remain on the market... This affirmation gave a material boost to both stocks on the primary belief that it should help their defense with associated litigation... In turn, their gains enabled the Dow to end the week on an upbeat note, even though it suffered a slight loss (-0.1%) for the entire week... Sticking with the good, bear in mind that Monday is Presidents' Day and that all U.S. markets will be closed for trading... NYSE Adv/Dec 1237/2131, Nasdaq Adv/Dec 1352/1714
2:32PM New 52-Week Highs: Oil and steel: Oil and steel stocks dominate the new 52-week high list. Tallies so far today for new highs vs lows are 152-17 (NYSE) and 65-38 (Nasdaq)... Sectors with good representation on the new high list today include Steel (CAS, CGA, CMC, LSS, MTL, MTLM, NSS, NUE, PKX, RESC, RS, SID, STLD, TONS, X), Integrated Oil (BP, COP, CVX, IMO, MRO, PTR, RD, TOT, XOM), Oil & Gas Exploration (ATPG, BR, CHK, DVN, EOG, NBL, NFX, OXY, UCL, VPI, XTO), Oil Services (BHI, CDIS, DO, DRQ, ESV, GRP, GSF, NBR, NOI, RDC, SII, VRCWFT), Cargo Ships (ATB, TRMD).
2:02PM QLT Inc: Aczone data demonstrates reduction in number & severity of acne lesions (QLTI) 15.42 +0.03: Co announces data from three clinical studies presented at the American Academy of Dermatology conference in New Orleans demonstrating that the Company's acne product Aczone (5% dapsone topical gel) reduces the number and severity of all lesion types in acne patients with no significant safety issues.Results from this study demonstrate a significant reduction in all lesion types (inflammatory, noninflammatory and total lesion counts) in patients using dapsone topical gel compared to the vehicle control group. An FDA decision on the new drug application seeking marketing approval (filed in 3Q04) is expected in 2H05.
1:04PM Treasuries close early and lower : The treasury market will close the shortened trading session lower with the yield curve tilting steeper. The long end of the curve extended overnight declines on the surprising surge in core PPI. The long bond came under pressure overnight as the market began speculating that US pension rules may force the Treasury to issue new 30-year bonds. Long-dated debt maturities are gaining popularity and speculation on the possibility of new supply hitting the market, in the form on brand new 30-year bonds, provided selling pressure. Treasuries will close the week lower with Greenspan's comments and inflation fears grabbing the credit for the sell off (see 9:33ET comment on bond tic). Despite the selling this week, some are calling for the long end of the curve to remain firmly supported due to the structural imbalance in supply and demand. Since the Treasury stopped issuing the 30-year bond in 2001, the long end has missed over $100B long bonds, which has shortened the treasury universe by year in aggregated duration. Asset/liability managers may continue to purchase 10- and 30-years as long duration remains scarce. Supply remains the key issue and the severe shortage in long duration securities has the potential to keep the long end of the curve at relatively low yields given the current state of the economy. Highlighting the economic calendar next week will be consumer confidence, CPI, durable orders, Q4 GDP-Prel, and existing home sales. The 10-years are -20/32nds yielding 4.258%
10:01AM Metrologic Inst receives additional contract modification of approx. $850,000 (MTLG) 20.50 +0.50:
9:16AM Gapping Down : Gapping down on disappointing earnings/guidance: NTGR -9.6%, ADIC -9.3% (also Bear Stearns downgrade), RAE -7%, ISNS -7%, INTU -1.9%, Other News: NTEC -7.6% (prices offering at $4/sh), DSCO -5.2% (stock offering), LGF -3.7% (announces convertible offering), CTIC -2.5% (profit taking from 12% move yesterday), BBY -1.1% (Goldman downgrade).
9:09AM Gapping Up : Gapping up on strong earnings/guidance: CRM +10.7%, NVDA +8.5%, AEIS +10.3% (also CIBC upgrade), AKAM +10%, CRYP +8.6%, TOPT +7.6%, VCLK +7.1%, MDRX +6.5%, PCLN +5.3%.... Other News: TIVO +10.8% (reaches 3 mln subs), PRM +8.6% (co's about.com to be sold to NYT), PKZ +6.6% (CIBC says co could have nearly $10/sh in cash by year-end), MAY +5.5% (FD resumes its takeover talks with May - WSJ), GRU +5.5%, SIGM +5% (started with an Outperform at Baird; tgt $20), MCIP +4.3% (Qwest plans revised offer for MCIP), MRK +3.8% (may return Vioxx to market), SINA +3.7%, FWHT +3.5% (London's The Sun newspaper chooses co's espotting.com over Google for paid listings - Forbes), TZOO +2.9%, SNIC +2.7% (added to JP Morgan's Focus List; tgt $21)... Under $3: SYNC +12.3% (posts largest non-GAAP profit in over 5 yrs).
12:22PM Campbell Soup Co (CPB) 28.39 -1.10: Soup's on! Well actually not really. Campbell Soup's Q2 disappointed the market with earnings of $0.57 per share - two cents below estimates. Considering the recent share action, the market was clearly expecting an upside beat. Revenues for the quarter rose 5.9% year/year to $2.22 bln actually ahead of estimates, yet declining earnings in its Soup, Sauces and Beverages division accounted for the bottom line miss.
The top line was driven by volume and mix adding 4% with price increases adding 1%. With 36% of sales coming from overseas, CPB enjoyed the benefits of a weaker dollar adding 2% to net sales. Its mainstay, the Soup, Sauces & Beverage segment saw sales up only 1%, as soup sales dropped 1% along with a 9% decline in the ready-to-serve segment, which faced stiff y/y comps. On the flip side was condensed soup sales up 4% and broth sales soaring 15%. Lower revenue growth, combined with higher operating costs including promotion spending and commodity costs, sent operating income sharply lower by 12% y/y.
It Baking & Snacking segment continues to perform well generating revenue growth of 9% and earnings of 12% due to favorable volume/mix and pricing gains. Co introduced new sugar free cookies and pot pies both adding to the unit's performance. However, this segment only accounts for 11% of total earnings. Intl Soup & Sauces (17% of total earnings) rose 10% in sales and 8% in profits with currency accounting for most of the upside. A bright spot was Asia showing strong volume growth during the quarter.
The guidance provided no relief with the co providing estimates that are in-line with consensus. For the full year, CPB reaffirmed earnings growth of 5-7%, which equates to EPS in the range of $1.66-1.69, versus consensus of $1.69.
The market did not take kindly to the report sending shares considerably lower. Overall, earnings quality was quite poor for the quarter. As such, we recommend investors let the dust settle and for the company to get a couple positive quarters under its belt before revisiting the name. As for now, the downward pressure is likely to remain. The one bright spot is its dividend yield of 3.82%. The stock is trading at 16.8x forward earnings compared to its peers General Mills (GIS) at 17.7x and ConAgra Foods (00C) at 18.0x. --Kimberly DuBord, Briefing.com
12:05PM Abbott Laboratories (ABT) $46.19 -0.37 (-0.8%) Abbott Labs raised its dividend this morning, to $0.275 per share, or an annual payment of $1.10 per share. At today's price of $46, this is equal to a yield of 2.4%. This puts it right in the middle of the yield range of the major drug companies. Merck and Johnson & Johnson have yields of 1.5% and 1.7%, respectively, while Pfizer and Bristol-Meyers have yields of 3.1% and 4.2%. However, ABT's stock performance over the past year has been much stronger than most other drug stocks, with JNJ a notable exception. This makes Abbott's yield an even more impressive number.
Ironically, the calculations for total returns on Abbott in 2004 will probably not include the total value of the spinoff of Hospira, which occurred in the spring of 2004. That spinoff, which initially had an approximately 10% immediate return to ABT returns, has been even larger, as HSP stock has risen an additional 15% since the spinoff in May of 2004.
Abbott has now raised its annual dividend every year for more than 30 years. This track record also ensures that Abbott will remain one of the select stocks that constitute the Mergent Dividend Achievers list. To be maintained on this list, a company must have continually increased its dividend continually for at least ten years. (For more on the Mergent Dividend Achievers list and index, see the Ahead of the Curve column of 23-Jun-04 "Book Review: Mergent's Dividend Achievers").
Dividends are slowly becoming more important to investors. The preferential tax treatment can be given only partial credit, however, as dividend stocks did not immediately respond to the preferential treatment, somewhat to our surprise. Now we think that dividend stocks are becoming more prominent in investors' focus because the traditional "growth stock superiority" paradigm is weakening. With Microsoft and Intel, once the crown-kings of "growth," both having been very poor investments over the past three years, the presumption that "growth trumps income" is no longer a given. In fact, Microsoft and Intel have both moved towards dividend payouts as a way to reward shareholders, in a tacit admission that keeping all earnings for reinvestment is not the "no-brainer" it used to be. Even KLA-Tencor, the semiconductor equipment company, is now paying a dividend. Are we seeing a gradual return to the old fashioned idea that the purpose of owning stock in a company is to get paid a share of the profits every year? That does seems to be happening, despite the strong disincentive of the double-taxation of a corporate dividend payment.
What this "slow shift in sentiment" towards a higher preference for dividends means is that companies like Abbott, that have a long history of both paying dividends and increasing them, are likely to become even more favored over time. Particularly if they keep increasing the dividend amount every year. Robert V. Green, Briefing.com
12:01PM Goldman Sachs (GS) 108.73 -1.87: There has been a rumor lately that makes sense but probably won't happen: Citigroup is said to be eyeing an acquistion of Goldman Sachs. That is a deal that would reshape the financial sector and make everyone else just a player.
Citigroup is already among the leaders in the financial services sector and owns Smith Barney. Goldman Sachs is one of the very best in terms of investment banking and trading; The combination of these strengths would be very powerful. The idea sprung up after Citigroup sold its insurance business to MetLife for $11.5 billion. That sounds like a healthy amount of cash, but remember that Goldman Sachs carries a $53 billion market cap, so the price tag would probably be north of $60 billion.
Goldman Sachs has long been an investment bank with a first rate trading house. The company also posted some solid results in 2004 with revenues topping the $29 billion mark, the highest since 2001. Earnings of $8.91 a share in 2004 were up significantly from $5.86 in the prior year, and the white-hot M&A market is driving speculation that the growth in earnings will continue.
While M&A is blistering, a market that is stuck in a trading range could prove troublesome for the company that has long been known for its trading expertise. Being a top notch shop, the company would still be able to garner a tidy sum from trading operations, but it is much easier to trade when the market is moving a particular direction. There is also the potential for the firm to participate in what is shaping up to be an improving IPO market, which should be a large EPS driver.
What investors should be focusing on is the earnings growth from Goldman Sachs. Earnings per share jumped 51% in 2004 and have grown at a rate of 27% over the last three years. This suggests a forward multiple that should be expanding, but has not. Trading at 11.7x next years earnings, the company is cheap compared to the market multiple that is generally in the high teens, but generally in line with peer valuations (Lehman Brothers and Merrill Lynch are both at 11x next year estimates).
A buyout would certainly be big news, but news that should not really be expected. The Citigroup rumor should eventually run its course. Investors should instead focus on the idea that Goldman will probably have even better earnings in 2005 as investment banking (M&A and IPO markets) picks up steam. Its not a law of physics, but better earnings tend to lead to better multiples and higher stock prices.
11:46AM Priceline.com Inc. (PCLN) 22.65 +1.09: It must be those hilarious Shatner and Nimoy commercials that turned what typically is a seasonally slow quarter for Priceline.com into a upside surprise. Co reported earnings after Thurs close of $8.8 mln, or $0.22 per share up 267% y/y and six cents ahead of estimates. Revenues for the quarter rose 8.2% year/year to $195 mln driven by retail airline tickets and Active Hotels acquisition.
The fourth quarter is typically slower as many consumers choose published fares over the Name Your Own Price® option during the holiday season. However, last Jan PCLN launched a new airline ticket product giving consumers the choice to shop around and compare published fares. Airline ticket unit bookings, which include both options, grew 61% y/y in-line with guidance. Hotel room night unit bookings including retail and opaque rose 51% y/y, while rental car booking gained 16% due to more inventory.
Overall, gross bookings rose 61% y/y to $413.5 mln with agency bookings of $196 mln. This is a highly profitable business. For the quarter stronger topline growth and lower cost of sales resulted in record gross margins of 26.4% due to higher hotel ASPs, Active Hotels acquisition, and opaque air sales. But growth came at a price as operating expenses rose 50% y/y mostly due to significant spending on advertising +44% and sales and marketing +54% and increased depreciation expense. Yet the pace of spending is still lower than revenues and bookings resulting in an operating margin of 23%.
Company expects Q1 EPS in the $0.18-0.22 range vs consensus of $0.23. For the full year it sees EPS of $1.18 vs consensus of $1.18. Co sees Q1 gross travel bookings growth of 30-35%. For the year, co expects ticket growth to come down with leisure fares remaining at low levels. Advertising spending will increase this year due to the launch of new products.
Priceline aims at being your full service online travel company. The departure away from a purely opaque service has paid off as the realization set in that customers prefer the choice. As Captain Kirk and Spock do their jobs increasing the retail option awareness, PCLN should continue to show positive momentum in this segment. Co is taking it one step further during second quarter launching a retail hotel product, which is sure to be the next growth driver. The one caveat being the retail business is less profitable than the opaque service, something to consider as co becomes more heavily retail weighted.
Going forward, Priceline is well positioned as a leader in online travel to leverage the longer term growth prospects as the world migrates more and more to the benefits of cyber travel. Stock is trading at a forward P/E of 19.2x with an earnings growth rate of 20%. --Kimberly DuBord, Briefing.com
9:48AM Page One - Focus Shifts from Earnings to Rates : The market sell-off yesterday reflected concerns over rising interest rates. Federal Reserve Chairman Greenspan had mentioned that risk on Wednesday, but the market held firm. Yesterday, the concerns justifiably broke through. Today, there are additional concerns.
The S&P 500 index enters today's trading down 5 points for the week. The 10-year note yield, meanwhile, had gone from 4.09% to 4.20% yesterday. This morning, it has jumped further to 4.24%. This isn't exactly dramatic, but it is a significant increase from the 3.97% hit on February 9. If the trend in the 10-year note yield keeps rising, it will not only solve the good Doctor Greenspan's conundrum, it very well may knock the stock market back.
There is little doubt that real GDP is on track for 3% or more growth. Earnings momentum is very strong. The uncertain variable for stock market valuation is interest rates. If rates remain as low as they are, then stocks may very well have a good year. But, with economic demand picking up, and with the slack in the economy slowing disappearing, long-term interest rates are likely to rise. That is likely whether or not inflation picks up.
This morning, there are also signs that inflation is picking up. January PPI was up a tame 0.3% after a similar drop in December. No problem there. Unfortunately, the core rate of PPI was up a huge, and unexpected, 0.8%. In 2004, the largest monthly gain was 0.3% and the entire year the core rate was up only 2.4%. This pop in pricing had some aberrant boosts, but even stable capital equipment prices were up 0.6%. It seems as if some pricing power has returned for producers. The bond market got whacked on the report. This one report doesn't mean inflation is back full force, but it legitimately raises a big red flag.
The corporate news is very light, but consistent with recent trends that have provided a boost to stocks. Qwest has indicated they will make a modified offer for MCI. Intuit and NVIDIA had good earnings reports, but Campbell Soup missed by 2 cents. Federated as renewed talks to acquire May Department Stores. Yesterday, Coke announced a 12% increase in their dividend. Thus, there is continued merger activity, good earnings, and dividend increases.
The question is whether those factors can produce a rising stock market. The answer depends largely on whether long-term rates rise significantly. The Fed looks likely to raise short-term rates to 3 1/2% or higher by the end of this year. If so, the 10-year note yield could rise to 4 3/4% or 5%. That seems likely to us, and that would limit stock market gains for the year. The prospect of firming inflation and rising rates is the reason our Market View is neutral. Dick Green, Briefing.com
http://biz.yahoo.com/mu/story.html